Literature DB >> 15481981

Influence of the linker in bispyridium compounds on the inhibition of human choline kinase.

Ana Conejo-García1, Mónica Báñez-Coronel, Rosario M Sánchez-Martín, Agustín Rodríguez-González, Angeles Ramos, Ana Ramírez de Molina, Antonio Espinosa, Miguel Angel Gallo, Joaquín M Campos, Juan Carlos Lacal.   

Abstract

Studies have been aimed to establish the structure-activity relationship that define choline kinase (ChoK) inhibitory potency and antiproliferative activity of a set of 25 bispyridinium compounds with electron-releasing groups at position 4. Here we report that, according to their inhibitory activities against human ChoK, the enzymatic inhibitory potency is closely related to the size of the linker, the 3,3'-biphenyl moiety being the most suitable. The N-methylanilino and its derivatives, 4-chloro-N-methylanilino and 3,5-dichloro-N-methylanilino, render higher ChoK inhibitory and antiproliferative activities against the HT-29 human colon cancer cell line.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15481981     DOI: 10.1021/jm0496537

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  7 in total

1.  A new family of choline kinase inhibitors with antiproliferative and antitumor activity derived from natural products.

Authors:  A Estévez-Braun; A G Ravelo; E Pérez-Sacau; J C Lacal
Journal:  Clin Transl Oncol       Date:  2014-12-04       Impact factor: 3.405

2.  Antiplasmodial activity and mechanism of action of RSM-932A, a promising synergistic inhibitor of Plasmodium falciparum choline kinase.

Authors:  Tahl Zimmerman; Carlos Moneriz; Amalia Diez; José Manuel Bautista; Teresa Gómez Del Pulgar; Arancha Cebrián; Juan Carlos Lacal
Journal:  Antimicrob Agents Chemother       Date:  2013-09-16       Impact factor: 5.191

3.  Crystal structures of human choline kinase isoforms in complex with hemicholinium-3: single amino acid near the active site influences inhibitor sensitivity.

Authors:  Bum Soo Hong; Abdellah Allali-Hassani; Wolfram Tempel; Patrick J Finerty; Farrell Mackenzie; Svetoslav Dimov; Masoud Vedadi; Hee-Won Park
Journal:  J Biol Chem       Date:  2010-03-18       Impact factor: 5.157

4.  Pharmacodynamic markers for choline kinase down-regulation in breast cancer cells.

Authors:  Sridhar Nimmagadda; Kristine Glunde; Martin G Pomper; Zaver M Bhujwalla
Journal:  Neoplasia       Date:  2009-05       Impact factor: 5.715

Review 5.  Choline kinase alpha-Putting the ChoK-hold on tumor metabolism.

Authors:  Sean P Arlauckas; Anatoliy V Popov; E James Delikatny
Journal:  Prog Lipid Res       Date:  2016-04-09       Impact factor: 16.195

6.  Biological Evaluation of New Thienopyridinium and Thienopyrimidinium Derivatives as Human Choline Kinase Inhibitors.

Authors:  Pilar María Luque-Navarro; Elena Mariotto; Marco Ballarotto; Gianluca Rubbini; Francisco José Aguilar-Troyano; Alberto Fasiolo; Archimede Torretta; Emilio Parisini; Antonio Macchiarulo; Alejandro Laso; Carmen Marco; Giampietro Viola; María Paz Carrasco-Jimenez; Luisa Carlota López-Cara
Journal:  Pharmaceutics       Date:  2022-03-27       Impact factor: 6.525

7.  The novel choline kinase inhibitor ICL-CCIC-0019 reprograms cellular metabolism and inhibits cancer cell growth.

Authors:  Sebastian Trousil; Maciej Kaliszczak; Zachary Schug; Quang-De Nguyen; Giampaolo Tomasi; Rosy Favicchio; Diana Brickute; Robin Fortt; Frazer J Twyman; Laurence Carroll; Andrew Kalusa; Naveenan Navaratnam; Thomas Adejumo; David Carling; Eyal Gottlieb; Eric O Aboagye
Journal:  Oncotarget       Date:  2016-06-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.